Local News

Duke to start trial of promising COVID treatment

If effective, the antibody trial could advance COVID care until a vaccine is developed by providing an antibody treatment.

Posted Updated
Coronavirus research
By
Heather Leah
, WRAL multiplatform producer

On Sunday, Duke announced that the Duke Human Vaccine Institute (DHVI) was given approval for a clinical trial that, if effective, could advance COVID care until a vaccine can be developed.

The approval means the DHVI can launch Phase 1 of the clinical trial for one of the most promising antibody treatments for COVID-19.

"This would be a temporary treatment until a vaccine is developed," said Duke Today in a statement.

The DHVI is also developing a pan-coronavirus vaccine to combat future iterations of COVID-19 or similar viruses, as well as if saliva could be used as an accurate indicator for COVID-19, according to Duke Today.

This video released by Duke Health Development provides a deeper look into the trials and potential for the antibody treatment.

More On This

 Credits 

Copyright 2024 by Capitol Broadcasting Company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.